Goldman Sachs downgrades Microsoft
Goldman Sachs downgraded Microsoft Corp. on Monday to neutral from buy, and lowered its price target on the software giant to $28 from $32.
Goldman Sachs upgraded Johnson & Johnson from Neutral to Buy, while downgrading Bristol-Myers Squibb Co..